SEC Form 4 · accession 0001193125-26-341528
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Earl Hensley
Officer — Chief Operating Officer
Period of report
Aug 6, 2026
Accepted (ET)
Aug 10, 2026 · 10:18 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 6, 2026 | M | 31,250 | — | A | 179,789 | D | |
| Common Stock | Aug 6, 2026 | F | 8,888 | $0.50 | D | 170,901 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Aug 6, 2026 | M | 31,250 | D | — | — | Common Stock | 31,250 | 343,750 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2The restricted stock units vest with 25% upon the first anniversary of date of grant (May 6, 2025) and then in twelve (12) equal quarterly installments thereafter.